U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
Go back to U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis| (NYSE: TAK) | Delayed: 17.55 +0.10 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.45 | 52 Week High | $0.55 | |||
| Open | $17.48 | 52 Week Low | $0.55 | |||
| Day High | $17.61 | P/E | N/A | |||
| Day Low | $17.42 | EPS | $-0.20 | |||
| Volume | 4,172,262 | |||||
